Bial - Portela & CA, S.A.
Records under this name other than the patents Bial - Portela & CA, S.A. holds now: patents now held by others, patents whose terms have ended, and its applications, pending or abandoned. None of them is counted in the 20 patents it holds.
Back to Bial - Portela & CA, S.A.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 8,907,099 | Nitrocatechol Derivatives as Comt Inhibitors Formerly held In force · Medium confidence | In force | Medium confidence | |
| US 8,168,793 | Nitrocatechol Derivatives as Comt Inhibitors Formerly held In force · High confidence | In force | High confidence | |
| US 8,975,410 | Crystal Forms of 5-[3-(2,5-Dichloro-4, 6-Dimethyl-1-OXY-PYRIDINE-3-YL)[1,2,4] OXADIAZOL-5-YL]-3-Nitrobenzene-1,2-DIOL Held by another company In force · High confidence | In force | High confidence | |
| US 11,434,242 | Dopamine-B-Hydroxylase Inhibitors Lapsed on the fee record Ended Sep 6, 2026 · High confidence | Lapsed on the fee record | Ended Sep 6, 2026 | High confidence |
| US 9,550,759 | Nitrocatechol Derivatives as Comt Inhibitors Term ended Term ended Jul 26, 2026 · Medium confidence | Term ended | Term ended Jul 26, 2026 | Medium confidence |
| US 10,336,740 | Nitrocatechol Derivatives as Comt Inhibitors Term ended Term ended Jul 26, 2026 · High confidence | Term ended | Term ended Jul 26, 2026 | High confidence |
| US 10,023,541 | Urea Compounds and Their Use as Enzyme Inhibitors Lapsed on the fee record Ended Jul 17, 2026 · Medium confidence | Lapsed on the fee record | Ended Jul 17, 2026 | Medium confidence |
| US 8,710,239 | Process for preparing synthetic intermediates of peripherally-selective inhibitors of dopamine-β-hydroxylase involving catalytic asymmetric hydrogenation Lapsed on the fee record Ended Apr 29, 2026 · USPTO record | Lapsed on the fee record | Ended Apr 29, 2026 | USPTO record |
| US 9,206,135 | Asymmetric catalytic reduction of oxcarbazepine Term ended Term ended Apr 21, 2026 · USPTO record | Term ended | Term ended Apr 21, 2026 | USPTO record |
| US 9,643,929 | Asymmetric catalytic reduction of oxcarbazepine Term ended Ended no later than Apr 21, 2026 · USPTO record | Term ended | Ended no later than Apr 21, 2026 | USPTO record |